COMPARABLE OUTCOME OF ALLOGENEIC VERSUS AUTOLOGOUS HEMATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTION IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE AND FLT3-ITD NEGATIVE
(Abstract release date: 05/19/16)
EHA Library. K Mahmoud H. 06/09/16; 135090; PB2190
Prof. Hossam K Mahmoud
Contributions
Contributions
Abstract
Abstract: PB2190
Type: Publication Only
Background
Optimal post-remission treatment for acute myeloid leukemia with normal karyotype (AML-NK) in first complete remission (CR1) is still not well-defined.
Aims
To compare the outcome of allogeneic versus autologous peripheral blood stem cell transplantation (PBSCT) in adult AML patients regarding toxicities of transplant procedure, transplant-related mortality (TRM), disease free survival (DFS) and overall survival (OS).
Methods
43 patients were included; 34 patients (with a median age 28 years) received myeloablative allogeneic PBSCT from a matched sibling donor while 9 patients (with a median age 36 years) received PBSC autograft. All patients had a normal karyotype, FLT3 ITD negative and were in CR1.
Results
After a median follow up of 21.5 months (0.3– 46.5), the cumulative 2-year OS and DFS in the allogeneic group were 73.5% and 70.6% respectively compared to 74.1% and 64.8%, respectively in the autologous group (p = 0.690 and 0.768). Increasing number of consolidation cycles (>3) and lower CD34 +ve stem cell dose were associated with lower relapse rates and higher DFS in the autologous group.
Conclusion
Preliminary data show comparable outcome of autologous compared to allogeneic PBSCT in patients with AML-NK and FLT3 ITD negative in CR1. In absence of matched sibling donor, autologous PBSCT may provide acceptable post-remission therapy for patients with low risk molecular profile.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Flt3-ITD, Stem cell transplant
Type: Publication Only
Background
Optimal post-remission treatment for acute myeloid leukemia with normal karyotype (AML-NK) in first complete remission (CR1) is still not well-defined.
Aims
To compare the outcome of allogeneic versus autologous peripheral blood stem cell transplantation (PBSCT) in adult AML patients regarding toxicities of transplant procedure, transplant-related mortality (TRM), disease free survival (DFS) and overall survival (OS).
Methods
43 patients were included; 34 patients (with a median age 28 years) received myeloablative allogeneic PBSCT from a matched sibling donor while 9 patients (with a median age 36 years) received PBSC autograft. All patients had a normal karyotype, FLT3 ITD negative and were in CR1.
Results
After a median follow up of 21.5 months (0.3– 46.5), the cumulative 2-year OS and DFS in the allogeneic group were 73.5% and 70.6% respectively compared to 74.1% and 64.8%, respectively in the autologous group (p = 0.690 and 0.768). Increasing number of consolidation cycles (>3) and lower CD34 +ve stem cell dose were associated with lower relapse rates and higher DFS in the autologous group.
Conclusion
Preliminary data show comparable outcome of autologous compared to allogeneic PBSCT in patients with AML-NK and FLT3 ITD negative in CR1. In absence of matched sibling donor, autologous PBSCT may provide acceptable post-remission therapy for patients with low risk molecular profile.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Flt3-ITD, Stem cell transplant
Abstract: PB2190
Type: Publication Only
Background
Optimal post-remission treatment for acute myeloid leukemia with normal karyotype (AML-NK) in first complete remission (CR1) is still not well-defined.
Aims
To compare the outcome of allogeneic versus autologous peripheral blood stem cell transplantation (PBSCT) in adult AML patients regarding toxicities of transplant procedure, transplant-related mortality (TRM), disease free survival (DFS) and overall survival (OS).
Methods
43 patients were included; 34 patients (with a median age 28 years) received myeloablative allogeneic PBSCT from a matched sibling donor while 9 patients (with a median age 36 years) received PBSC autograft. All patients had a normal karyotype, FLT3 ITD negative and were in CR1.
Results
After a median follow up of 21.5 months (0.3– 46.5), the cumulative 2-year OS and DFS in the allogeneic group were 73.5% and 70.6% respectively compared to 74.1% and 64.8%, respectively in the autologous group (p = 0.690 and 0.768). Increasing number of consolidation cycles (>3) and lower CD34 +ve stem cell dose were associated with lower relapse rates and higher DFS in the autologous group.
Conclusion
Preliminary data show comparable outcome of autologous compared to allogeneic PBSCT in patients with AML-NK and FLT3 ITD negative in CR1. In absence of matched sibling donor, autologous PBSCT may provide acceptable post-remission therapy for patients with low risk molecular profile.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Flt3-ITD, Stem cell transplant
Type: Publication Only
Background
Optimal post-remission treatment for acute myeloid leukemia with normal karyotype (AML-NK) in first complete remission (CR1) is still not well-defined.
Aims
To compare the outcome of allogeneic versus autologous peripheral blood stem cell transplantation (PBSCT) in adult AML patients regarding toxicities of transplant procedure, transplant-related mortality (TRM), disease free survival (DFS) and overall survival (OS).
Methods
43 patients were included; 34 patients (with a median age 28 years) received myeloablative allogeneic PBSCT from a matched sibling donor while 9 patients (with a median age 36 years) received PBSC autograft. All patients had a normal karyotype, FLT3 ITD negative and were in CR1.
Results
After a median follow up of 21.5 months (0.3– 46.5), the cumulative 2-year OS and DFS in the allogeneic group were 73.5% and 70.6% respectively compared to 74.1% and 64.8%, respectively in the autologous group (p = 0.690 and 0.768). Increasing number of consolidation cycles (>3) and lower CD34 +ve stem cell dose were associated with lower relapse rates and higher DFS in the autologous group.
Conclusion
Preliminary data show comparable outcome of autologous compared to allogeneic PBSCT in patients with AML-NK and FLT3 ITD negative in CR1. In absence of matched sibling donor, autologous PBSCT may provide acceptable post-remission therapy for patients with low risk molecular profile.
Session topic: E-poster
Keyword(s): Acute myeloid leukemia, Flt3-ITD, Stem cell transplant
{{ help_message }}
{{filter}}